Pharmaceuticals and Medical Devices Agency.https://www.pmda.go.jp/review-services/drug-reviews/review-information/p-drugs/0028.html. Accessed 17 Jul 2024.

Akagi K, Oki E, Taniguchi H, et al. Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci. 2021;112:1105–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patil DT, Bronner MP, Portier BP, et al. A five-marker panel in a multiplex PCR accurately detects microsatellite instability-high colorectal tumors without control DNA. Diagn Mol Pathol. 2012;21:127–33.

Article  CAS  PubMed  Google Scholar 

Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579–86.

Article  PubMed  PubMed Central  Google Scholar 

Chakrabarti S, Bucheit L, Starr JS, et al. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. J Immunother Cancer. 2022;10:e004485.

Article  PubMed  PubMed Central  Google Scholar 

Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1–10.

Article  CAS  PubMed  Google Scholar 

Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site-when a biomarker defines the indication. N Engl J Med. 2017;377:1409–12.

Article  PubMed  Google Scholar 

Yamaguchi J, Yokoyama Y, Fujii T, et al. Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01). Ann Surg. 2022;275:1043–9.

Article  PubMed  Google Scholar 

Hashimoto D, Satoi S, Fujii T, et al. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? a position paper by experts in pancreatic surgery at the joint meeting of the international association of pancreatology (IAP) & the Japan pancreas society (JPS) 2022 in Kyoto. Pancreatology. 2023;23:682–8.

Article  PubMed  Google Scholar 

Nagai M, Wright MJ, Ding D, et al. Oncologic resection of pancreatic cancer with isolated liver metastasis: favorable outcomes in select patients. J Hepatobiliary Pancreat Sci. 2023;30:1025–35.

Article  PubMed  PubMed Central  Google Scholar 

Hank T, Klaiber U, Hinz U, et al. Oncological outcome of conversion surgery after preoperative chemotherapy for metastatic pancreatic cancer. Ann Surg. 2023;277(5):e1089–98.

Article  PubMed  Google Scholar 

Hidaka Y, Arigami T, Osako Y, et al. Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report. World J Surg Oncol. 2022;20:193.

Article  PubMed  PubMed Central  Google Scholar 

Zhang S, Huang Y, Chen M, et al. Immunochemotherapy includes pembrolizumab for stage IIIB lung squamous cell carcinoma: a case report. Ann Transl Med. 2022;10:1028.

Article  PubMed  PubMed Central  Google Scholar 

Tong BC, Gu L, Wang X, et al. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022;163:427–36.

Article  PubMed  Google Scholar 

Lee M, Cho YJ, Jung H-S, et al. Collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy. Ann Hepatobiliary Pancreat Surg. 2023;27:141–50.

Article  PubMed  PubMed Central  Google Scholar 

Kawazoe T, Ito S, Ohgaki K, et al. Successful conversion surgery following chemotherapy with an immune checkpoint inhibitor in an older adult patient with stage IVB esophageal squamous cell carcinoma: a case report. Surg Case Rep. 2023;9:51.

Article  PubMed  PubMed Central  Google Scholar 

Guidelines for peritoneal disseminated disease. 2021 edition; 2021:99.https://fukumakuhashu.jp/guideline.html. Accessed 17 Jul 2024.

Kyakumoto Y, Takadate T, Mizuma M, et al. A case of successful adjuvant surgery for the pancreas head cancer with peritoneal metastasis. Gan To Kagaku Ryoho. 2017;44:1880–2.

PubMed  Google Scholar 

Yamada S, Fujii T, Yamamoto T, et al. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Br J Surg. 2020;107:1811–7.

Article  CAS  PubMed  Google Scholar 

Fukasawa M, Watanabe T, Tanaka H, et al. Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chemotherapy for positive peritoneal cytology. J Hepatobiliary Pancreat Sci. 2023;30:1261–72.

Article  PubMed  Google Scholar 

Igarashi T, Fukasawa M, Watanabe T, et al. Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peritoneal washing cytology. Ann Gastroenterol Surg. 2023;8:124–32.

Article  PubMed  PubMed Central  Google Scholar 

Igarashi T, Yamada S, Hoshino Y, et al. Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: results of a dual-center study. Ann Gastroenterol Surg. 2022;7:157–66.

Article  PubMed  PubMed Central  Google Scholar